Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study

被引:0
|
作者
Santoro, M. M. [1 ]
Gianotti, N. [2 ]
Galli, L. [2 ]
Scutari, R. [1 ]
Alteri, C. [3 ]
Poli, A. [2 ]
Piermatteo, L. [1 ]
Bigoloni, A. [2 ]
Perno, C. F. [3 ]
Lazzarin, A. [2 ]
Ceccherini-Silberstein, F. [1 ]
Castagna, A. [2 ,4 ]
机构
[1] Univ Roma Tor Vergata, Rome, Italy
[2] IRCCS San Raffaele, Infect Dis, Milan, Italy
[3] Univ Milan, Milan, Italy
[4] Univ Vita Salute San Raffaele, Milan, Italy
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
PE3/3
引用
收藏
页码:89 / 89
页数:1
相关论文
共 1 条
  • [1] Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients
    Galizzi, Nadia
    Poli, Andrea
    Galli, Laura
    Muccini, Camilla
    Mastrangelo, Andrea
    Dell'Acqua, Raffaele
    Maillard, Myriam
    Bossolasco, Simona
    Cinque, Paola
    Lazzarin, Adriano
    Castagna, Antonella
    Gianotti, Nicola
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (03)